Hagiwara A, Takahashi T, Ueda T, Lee R, Takeda M, Itoh T
First Department of Surgery, Kyoto Prefectural University of Medicine, Japan.
Surgery. 1988 Nov;104(5):874-81.
A new dosage form of activated carbon particles adsorbing mitomycin C (MMC-CH) was studied for its therapeutic effects on peritoneal dissemination in both animal experiments and preliminary clinical trials. Rabbits with peritoneal dissemination induced by intraperitoneal transplanted VX2 carcinoma were used as experimental models. Seven days after intraperitoneal transplantation of VX2 carcinoma, mitomycin C at 1 mg/kg in the form of MMC-CH or at 0.185 mg/kg in the form of mitomycin C aqueous solution was given intraperitoneally. The two doses were equal in toxicity. MMC-CH extended survival time statistically significantly longer than did mitomycin C aqueous solution. Preliminary clinical trial with MMC-CH has been made in eight patients with gastric cancer and peritoneal dissemination, with no control group. MMC-CH, 60 to 100 mg/person, was given intraperitoneally before the surgical wound was closed. Patients were observed for more than 1 year. Five of the eight patients survived more than 1 year, and the mean survival time was 13.9 months, whereas in the patients treated previously without MMC-CH the 1-year survival rate was 17% and the mean survival time was 6.5 months. Side effects were temporary and tolerable.
研究了一种吸附丝裂霉素C的活性炭颗粒新剂型（MMC-CH）在动物实验和初步临床试验中对腹膜播散的治疗效果。将腹腔移植VX2癌诱导腹膜播散的兔子用作实验模型。在VX2癌腹腔移植7天后，以MMC-CH形式腹腔注射1mg/kg丝裂霉素C或以丝裂霉素C水溶液形式腹腔注射0.185mg/kg丝裂霉素C。两种剂量的毒性相同。MMC-CH在统计学上显著延长了生存期，比丝裂霉素C水溶液延长的时间更长。已对8例患有胃癌和腹膜播散的患者进行了MMC-CH的初步临床试验，未设对照组。在手术伤口缝合前腹腔注射MMC-CH，60至100mg/人。对患者进行了1年以上的观察。8例患者中有5例存活超过1年，平均生存期为13.9个月，而之前未接受MMC-CH治疗的患者1年生存率为17%，平均生存期为6.5个月。副作用是暂时的且可耐受。
